Cancer Treatment-Induced @entity604 in XXXX with @entity0 .

@entity1 @entity172 @entity0 @entity174 @entity5 @entity604 @entity170 @entity79 @entity1176 @entity7730
@entity170 is one of the most frequent diseases in postmenopausal @entity1 , leading to an increased @entity174 risk due to the physiologic loss of the bone protective effects of @entity172 . Hereby, several risk factors for @entity174 such as prevalent @entity174 , low @entity79 ( @entity79 ), age, low body mass index, family history, tendency to falls, smoking, use of SSRIs, glucocorticoid use etc. have been identified. In addition, the further reduction in endogenous @entity172 with @entity7730 ( @entity7730 ), @entity1176 analoga or aromatase inhibitors (AIs) continuously increases @entity174 risk. @entity0 ( @entity0 ) on the other hand is the most frequent @entity5 type in @entity1 . Recent reports indicate a continuous increased incidence, whereas mortality, due to early diagnosis and treatment improvements, is decreasing. @entity5 characteristics, radiation, @entity7730 , antibody treatment as well as endocrine treatment have been included into the adjuvant clinical treatment setting. Some but not all of these @entity5 -specific treatments interfere with bone turnover, leading to an accelerated @entity604 referred to as @entity5 treatment-induced @entity604 (CTIBL). Whereas @entity7730 leads to an unspecific increase in bone resorption, AI reduces residual serum endogenous @entity172 level and is associated with a decrease in @entity79 and increased @entity174 risk. Independent of the type of AI administered, @entity604 is 2-3-fold increased compared with healthy, age-matched postmenopausal controls. Therefore, several guidelines have emerged to help managing CTIBL in @entity1 with @entity0 including strategies to identify and treat those at highest risk for @entity174 . This review summarizes the current knowledge on CTIBL and fracturing risk and indicates preventative strategies.
